BlackRock’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
Other funds holding MLYS
BlackRock's MLYS Position: Q3 2026 in Review
BlackRock increased its Mineralys Therapeutics (MLYS) stake by 4.8% in Q3 2026, buying an estimated $7.76M and bringing the position to 6,172,153 shares worth $155M. The position accounts for ﹤0.01% of the portfolio, ranked #1926.
BlackRock first reported a position in MLYS in Q1 2023 and has held it in 15 quarters since. The position peaked at $159M in Q2 2026. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.
- BlackRock held 6,172,153 shares of Mineralys Therapeutics worth $155M as of Q3 2026.
- BlackRock bought 285,115 Mineralys Therapeutics shares in Q3 2026, an estimated $7.76M.
- Mineralys Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #1926 holding.
- BlackRock first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 15 quarters since.
- BlackRock's Mineralys Therapeutics position peaked at $159M in Q2 2026.
- 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.
Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.